



Life Science REIT plc
(the "Company")

LEI: 213800RG7JNX7K8F7525

3 June 2025

Annual General Meeting ("AGM") Results

The Company announces that at its Annual General Meeting held earlier today all the resolutions set out in the Notice of Annual General Meeting were passed. All resolutions were voted on by way of a poll. The results of the poll for each resolution were as follows:

Resolution	For		Against		Votes Withheld (No. of shares)
	No. of shares	%	No. of shares	%	
1. To receive and approve the annual report and financial statements	170,107,273	99.00%	1,725,065	1.00%	73,670
2. To receive and approve the Directors' remuneration report	170,955,999	99.53%	803,872	0.47%	146,137
3. To approve the Directors' remuneration policy	170,735,896	99.40%	1,025,053	0.60%	145,059
4. To approve the Company's dividend payment policy	171,288,518	99.70%	509,154	0.30%	108,336
5. To re-elect Claire Boyle as a Director of the Company	162,069,299	94.32%	9,756,368	5.68%	80,341
6. To re-elect Mike Taylor as a Director of the Company	168,458,021	98.04%	3,367,646	1.96%	80,341
7. To re-elect Richard Howell as a Director of the Company	168,458,021	98.04%	3,367,646	1.96%	80,341
8. To re-elect Sally Ann Forsyth as a Director of the Company	160,401,176	93.35%	11,424,491	6.65%	80,341
9. To re-appoint Deloitte LLP as Auditor to the Company	171,653,308	99.90%	179,030	0.10%	73,670
10. To authorise the Audit and Risk Committee to determine the remuneration of the Auditor to the Company	171,676,363	99.92%	132,968	0.08%	96,677
11. To authorise the Directors to allot equity securities	154,506,973	93.03%	11,569,169	6.97%	5,829,866
12. To authorise the Directors to disapply pre-emption rights*	144,045,004	98.70%	22,000,000	12.30%	5,829,866

disapply pre-emption rights	144,015,864	86.72%	22,060,278	13.28%	5,829,866
13. To authorise the Directors to disapply pre-emption rights for the purposes of financing an acquisition or other capital investment*	143,882,140	86.70%	22,067,565	13.30%	5,956,303
14. To approve the purchase of the Company's own shares*	167,087,012	97.24%	4,745,326	2.76%	73,670
15. That a general meeting, other than an AGM, may be called on not less than 14 clear days' notice*	168,132,129	97.85%	3,700,209	2.15%	73,670

**special resolution*

NOTES:

1. All resolutions were passed.
2. Percentages have been rounded to two decimal places.
3. Proxy appointments which gave discretion to the Chair of the AGM have been included in the "For" total for the appropriate resolution.
4. Votes "For" and "Against" any resolution are expressed as a percentage of votes validly cast for that resolution.
5. A "Vote withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against" any resolution.
6. The number of shares in issue at 10:00 am. on 30 May 2025 was 350,000,000 ordinary shares, carrying one vote each, and at that time, the Company did not hold any shares in treasury.
7. The full text of the resolutions passed at the AGM can be found in the Notice of Annual General Meeting which is available on the Company's website at <https://lifesciencereit.co.uk/investors/shareholder-information/>

Enquiries:

MUFG Corporate Governance Limited - Company Secretary
labs_cosec@cm.mpms.mufg.com

Ironstone Asset Management - Investment Adviser
Simon Farnsworth/ Joanna Waddingham

via FTI Consulting below

Panmure Liberum - Financial Adviser & Corporate Broker
Alex Collins / Tom Scrivens

+44 20 7886 2500

G10 Capital Limited - AIFM
Verity Morgan-Jones / Maria Baldwin

+44 20 7397 5450

FTI Consulting - PR Adviser
Dido Laurimore / Richard Gotla / Oliver Parsons

+44 20 3727 1000

LifeScienceReit@fticonsulting.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this

communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

RAGFJMITMTAMBPA